arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zymeworks Inc.

ZYME
$27.51 ▼ -0.06 (-0.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zymeworks Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0B
Dividend Yield
Revenue Growth -90.6%
Op. Margin None
ROIC -52.2%
FCF / Share $-0.44
Trailing P/E
Price / Book 24.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.59M
↓ -90.6%
Net Income Profit after all expenses
$-44.16M
↓ -95.1%
Operating Margin Operating profit as % of sales
-80.1%
↓ -5688.4% 3th
FCF / Share Free cash flow per share
$-0.44
↑ +28.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
23
Cash Quality
37

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 24 quarters